Mechanism of the Ca$^{2+}$-induced Enhancement of the Intrinsic Factor VIIa Activity*

Received for publication, January 31, 2008, and in revised form, July 7, 2008. Published, IBC Papers in Press, July 17, 2008, DOI 10.1074/jbc.M800841200

Jais R. Bjelke*, Ole H. Olsen*, Michel Fodje*, L. Anders Svensson†, Susanne Bang*, Gert Bolt†, Birthe B. Kragelund**, and Egon Persson*†

From the Departments of *Protein Structure and Biophysics, †Haemostasis Biochemistry, *Protein Purification, and ‡Mammalian Cell Technology, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv and the **Structural Biology and NMR Laboratory, Department of Biology, Copenhagen University, DK-2200 Copenhagen N, Denmark

The intrinsic activity of coagulation factor VIIa (FVIIa) is dependent on Ca$^{2+}$ binding to a loop (residues 210–220) in the protease domain. Structural analysis revealed that Ca$^{2+}$ may enhance the activity by attenuating electrostatic repulsion of Glu$^{296}$ and/or by facilitating interactions between the loop and Lys$^{161}$ in the N-terminal tail. In support of the first mechanism, the mutations E296V and D212N resulted in similar, about 2-fold, enhancements of the amidolytic activity. Moreover, mutation of the Lys$^{161}$-interactive residue Asp$^{217}$ or Asp$^{219}$ to Ala reduced the amidolytic activity by 40–50%, whereas the K161A mutation resulted in 80% reduction. Hence one of these Asp residues in the Ca$^{2+}$-binding loop appears to suffice for some residual interaction with Lys$^{161}$, whereas the more severe effect upon replacement of Lys$^{161}$ is due to abrogation of the interaction with the N-terminal tail. However, Ca$^{2+}$-attenuation of the repulsion between Asp$^{212}$ and Glu$^{296}$ keeps the activity above that of apoFVIIa. Altogether, our data suggest that repulsion involving Asp$^{212}$ in the Ca$^{2+}$-binding loop suppresses FVIIa activity and that optimal activity requires a favorable interaction between the Ca$^{2+}$-binding loop and the N-terminal tail. Crystal structures of tissue factor-bound FVIIa$_{D212N}$ and FVIIa$_{V158D/E296V/M298Q}$ revealed altered hydrogen bond networks, resembling those in factor Xa and thrombin, after introduction of the D212N and E296V mutations plausibly responding to tethering of the N-terminal tail to the activation domain. The charge repulsion between the Ca$^{2+}$-binding loop and the activation domain appeared to be either relieved by charge removal and new hydrogen bonds (D212N) or abolished (E296V). We propose that Ca$^{2+}$ stimulates the intrinsic FVIIa activity by a combination of charge neutralization and loop stabilization.

---

The proteolytically activated form of blood coagulation factor VII (FVII),

2 FVIIa, behaves zymogen-like with low enzymatic activity as opposed to other, constitutively active serine proteases of the coagulation cascade. Only upon full activation of FVIIa by tissue factor (TF) binding is the cascade initiated by activation of coagulation factors IX and X, in turn leading to the generation of thrombin (1–3). Thrombin then cleaves fibrinogen to fibrin that polymerizes to give a clot that permanently cessates the bleeding (4, 5).

As for all trypsin-like serine proteases, the activation of enzymes in the coagulation cascade involves tethering of the N terminus, created after proteolytic cleavage of the zymogen forms, to the activation domain within the protease domain with concomitant stabilization of its three activation loops (6–8). In the active conformation of FVIIa, a salt bridge is formed between the N-terminal α-amino group of Ile$^{153}$ and the side chain of Asp$^{243}$ in the activation pocket of the activation domain.3 The latter is positioned next to the active site Ser$^{344}$ (9). FVIIa is only fully active upon TF binding and Ca$^{2+}$-binding to nine sites located in three different domains, including the Ca$^{2+}$-binding Glu$^{210}$ – Glu$^{220}$ loop in the protease domain (10, 11). Upon binding of the cofactors, an activity increase of several 1,000-fold is observed, in part by shifting the equilibrium from the zymogen-like form toward the catalytically active conformation of FVIIa (12, 13). Ca$^{2+}$ binding alone leads to a more than 10-fold increase in activity (14).

Interestingly, the activating effect of TF has been partially mimicked by means of grafting (see Ref. 15) and site-directed mutagenesis (see Ref. 16) of the loop succeeding the TF-interactive helix (residues 306–312) yielding FVIIa variants with increased intrinsic activity. Replacements of residues in the vicinity of the activation domain have also improved FVIIa activity. Notably, the residues Val$^{158}$, Glu$^{296}$, and Met$^{298}$ appear to form a zymogenicity-determining triad close to the activation domain. Replacements by the corresponding three residues in homologous coagulation factors have resulted in FVIIa variants with substantially increased intrinsic activity (17–19). The most dramatic increase requires conversion of the entire 3-residue motif to that found in thrombin and factor IXa (V158D/E296V/M298Q–FVIIa) (FVIIa$_{PVQ}$) (17). Mutation of Glu$^{296}$ to Val reduced the dependence on Ca$^{2+}$ suggesting a link to the stimulatory Ca$^{2+}$ effect, possibly via insertion of the N terminus (20). Moreover, residue 296 has been linked to macromolecular substrate-induced maturation of the catalytic cleft as inferred from a conformational change upon binding of a monoclonal antibody (21, 22).

---

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed. Tel: 45-4443-4351; Fax: 45-4466-3450; E-mail: egp@novonordisk.com.

2 The abbreviations used are: FVII/VIIa, coagulation factor VII/VIIa; TF, tissue factor; AT, antithrombin; stTF-(1–209), soluble TF, residues 1–209; Z, benzylxoycarbonyl.

3 Amino acid sequence numbering (FVIIa, chymotrypsinogen) is as follows: 153, 156; 159, 19; 157, 20; 158, 21; 161, 24; 210, 70; 211, 71; 212, 72; 213, 73; 214, 74; 217, 77; 219, 79; 220, 80; 283, 140; 295, 153; 296, 154; 297, 155, 298, 156; 306, 164; 312, 170; 343, 194.
Using a change-of-function mutagenesis and crystal structural approach, we have further investigated the zymogenicity and Ca\(^{2+}\) dependence of FVIIa. We hypothesized that the effects of Ca\(^{2+}\) on FVIIa activity are through stabilization of the Ca\(^{2+}\)-binding loop, i.e. stabilization of the interaction(s) of Asp\(^{217}\)/Asp\(^{219}\) with Lys\(^{161}\) in the N-terminal tail, and through alleviation of charge repulsion between the loop, primarily Asp\(^{212}\), and the nearby Glu\(^{296}\). The latter residue had been mutated in an earlier study (20) and the other four were replaced in the present study to obtain a complete set of variants to test the hypothesis. Lys\(^{161}\), Asp\(^{217}\), and Asp\(^{219}\) were replaced by Ala to remove the charges without introducing new interactions (van der Waals or hydrogen bonds). Asp\(^{212}\) was replaced by Asn hereby removing the charge with minimal alteration.

Our data suggest that Ca\(^{2+}\) binding to the 210–220 loop in the protease domain of FVIIa promotes the intrinsic activity through stabilization of electrostatic interactions of Asp\(^{217}\) and Asp\(^{219}\) with Lys\(^{161}\) in the N-terminal tail and mitigation of the repulsion by Asp\(^{212}\) of Glu\(^{296}\) located close to loop 1 of the activation domain. Indeed, Asp\(^{212}\) was identified as a new zymogenicity determinant, because the charge removal led to an increased intrinsic activity and degree of N terminus burial.

**MATERIALS AND METHODS**

**Protein Preparations**—The construct pLN174 consisting of the cDNA encoding wild-type human FVII inserted into pZem219b was previously described (23). The mutations were introduced into pLN174 using the QuikChange kit (Stratagene, La Jolla, CA) and the following primers (only sense primers were introduced into pLN174 using the QuikChange kit (Stratagene, La Jolla, CA) and the following primers (only sense primers given), with base substitutions in italics and the affected codons underlined, were used to introduce the indicated mutations: K161A, 5'-G GGG GGC AAG GTG TGC CCC GCA GGG GAG TGT TGG CCA TGG CAG GTC C; D212N, 5'-C CTG ATC GCG GTG CTG GGC GAG CAC AAC CTC AGC GAG GAC GC; D212A, 5'-C TCT AGC GAG CAC GCC GGG GAT GAG C; D219A, 5'-G CAC GAC GGG GCT GAG GAC AGC C.

Baby hamster kidney and Chinese hamster ovary-K1 cell lines producing the FVIIa variants were generated as described (24). The baby hamster kidney cell line producing the V158D/M298Q mutant was previously described (17). Purification of wild-type and mutant FVII from cell culture medium was carried out essentially as described (17, 25) using an anion-exchange and immunoaffinity based purification process. Activation of zymogen FVII was performed either by autoactivation or by the use of Sepharose-coupled FXa or soluble FIXa. The latter was separated from FVIIa using an immunoaffinity column. FVIIa concentrations were estimated from absorbance measurements at 280 nm. Active FVIIa enzyme concentrations were determined by an amidolytic activity assay; the activities of the FVIIa variants, diluted to 10 nM and mixed with 50 nM sTF, were compared with those of mixtures of 10 nM sTF and 50 nM FVIIa variant (from which the activity of excess FVIIa variant had been subtracted). If the activities of the two mixtures were indistinguishable, the originally estimated concentration of FVIIa variant equaled the active concentration and if not, the active concentration was adjusted ([active FVIIa] = estimated [FVIIa] multiplied by the activity ratio (10 nM FVIIa plus 50 nM sTF/10 nm sTF plus 50 nm FVIIa)). This method allows for the calculation of relative activities (Table 1). Plasma-derived FX and FXa were from Enzyme Research Laboratories (South Bend, IN). Active site-inhibited FVIIa variants were obtained by incubation with the inhibitor PhePheArg-arginomethylketone essentially as described (26). Soluble TF (sTF, residues 1–209) was produced as described (27). Antithrombin (AT) was from Hemitoglog Technologies (Essex Junction, VT).

**Amidolytic and Proteolytic Activity Assays**—All measurements were performed at room temperature in 50 mM Hapes, pH 7.4, containing 0.1 mM NaCl, 5 mM CaCl\(_2\), and 1 mg/ml bovine serum albumin. The amidolytic activity of variant/wild-type FVIIa (100 nM) was measured with or without 1 μM sTF. Initial kinetic rates were determined from absorbance (405 nm) development using the chromogenic substrate S-2288 (2.5 mM) (H-d-Ile-Pro-Arg-p-nitroanilide, Chromogenix) monitored for 5–30 min with readings every 30 s in a SpectraMax 340 microplate reader (Global Medical Instrumentation, Inc., MN). The proteolytic activities were measured by incubating 50 nM FVIIa variant with 1 μM FX for 40 min, stopping the reaction with excess EDTA, and measuring the resulting FXa activity by adding 0.5 mM S-2765 (Z-d-Arg-Gly-Arg-p-nitroanilide, Chromogenix). The rate of substrate hydrolysis catalyzed by a FVIIa mutant was divided by the rate seen with wild-type FVIIa to obtain the relative activity.

**Carbamylation Assay**—The carbamylation of Ile\(^{153}\) was performed by incubation of 100 nM to 2 μM variant/wild-type FVIIa with 0.2 mM potassium cyanate in assay buffer (see above) without bovine serum albumin. Samples were withdrawn at different time points and diluted 10-fold in assay buffer containing 5 mM S-2288 and hydrolysis was monitored for 2–5 min as described for the amidolytic assay.

**AT Inhibition Assay**—AT inhibition was performed by incubation of 100 nM variant/wild-type FVIIa with 100 μg/ml AT and 1 unit/ml heparin in assay buffer. Samples were withdrawn at different time points and diluted 2-fold in assay buffer containing 5 mM S-2288 and hydrolysis monitored for 2–5 min.

**Crystallization Conditions**—Active site-inhibited FVIIa mutants in complex with sTF (1–209) were purified using a Superdex75 16/60 prep-grade column (Amersham Biosciences). A buffer composition of 10 mM Tris, pH 7.5, 100 mM NaCl, and 15 mM CaCl\(_2\) was used. Crystals were obtained using the hanging drop vapor diffusion method using 0.1 mM sodium citrate, pH 5.6, 16% (w/v) PEG4000, 12% (v/v) 1-propanol, and a protein concentration of 3–4 mg/ml (28). The crystals grew as thin plates with dimensions up to 0.4 x 0.6 x 0.05 mm.

**Crystal Data Collection and Processing**—Crystallographic data collection was performed at the synchrotron beam lines MaxLab 711/911 (MaxLab, Lund, Sweden) (29). Crystals were flash frozen in a cryoprotective solution composed of precipitating solution with 20% (v/v) glycerol. Data reduction calculations were performed with the XDS software package (30). The structures were solved by the molecular replacement method using the Molrep program, part of the CCP4 package (31, 32), and PDB code 1DAN as a search model (9). Model building was performed using the Coot program (33) and maximum likelihood based iterative refinement, initially performed as a rigid
body refinement, using the Refmac5 program, part of the CCP4 package (32, 34). The PyMOL Molecular Graphics System (35) was used for structure analysis and creation of figures.

RESULTS

Functional Characterization—The intrinsic amidolytic activities were measured for FVIIaD212N, FVIIaDVQ, and Ala mutants at positions Lys161, Asp217, and Asp219 using the peptidyl substrate S-2288 (Table 1). It is worth mentioning that none of the removed Asp residues (212, 217, and 219) are side chain Ca2+ ligands (9). The amidolytic activity of free FVIIaD212N was increased 2-fold compared with wild-type FVIIa, whereas that of FVIIaDVQ was considerably higher as previously reported (17, 20). The three Ala mutants exhibited reduced amidolytic activities. In the presence of sTF-(1–209), no significant difference in activity between FVIIaD212N, FVIIaDVQ, and wild-type FVIIa could be observed, indicating that the activity-enhancing effects of the mutations are manifested only in the absence of the cofactor. In contrast, FVIIaK161A, FVIIaD217A, and FVIIaD219A displayed a similar reduction in amidolytic activity whether bound to sTF or not.

To further characterize the variants with increased intrinsic activity, we performed inhibition experiments using the serpin AT in the presence of heparin. Previous studies have demonstrated that TF enhances the susceptibility to inhibition by AT/heparin 33-fold compared with the free form of FVIIa as a result of TF-induced maturation of the active site (36, 37). Similarly, increased AT inhibition rates of FVIIa variants with increased intrinsic activities have also been shown to correlate with the levels of intrinsic amidolytic activity (17, 20). The three Ala mutants exhibited reduced amidolytic activities. In the presence of sTF-(1–209), no significant difference in activity between FVIIaD212N, FVIIaDVQ, and wild-type FVIIa could be observed, indicating that the activity-enhancing effects of the mutations are manifested only in the absence of the cofactor. In contrast, FVIIaK161A, FVIIaD217A, and FVIIaD219A displayed a similar reduction in amidolytic activity whether bound to sTF or not.

TABLE 1

| Relative amidolytic activity | Relative proteolytic activity | Relative carbamylation rate | Relative antithrombin inhibition rate |
|-----------------------------|-----------------------------|-----------------------------|------------------------------------|
| Wild-type                   | 1.0                         | 1.0                         | 1.0                                |
| FVIIaD212N                  | 2.0 ± 0.2                   | 0.3 ± 0.0                   | 0.5 ± 0.1                          | 1.8 ± 0.04 |
| FVIIaDVQ                    | 6.2 ± 0.6                   | 25 ± 34*                    | 0.1 ± 0.1                          | 4.9 ± 0.6  |
| FVIIaK161A                  | 0.2 ± 0.0                   | 0.2 ± 0.0                   | ND†                                | ND         |
| FVIIaD217A                  | 0.5 ± 0.1                   | 0.4 ± 0.0                   | ND                                 | ND         |
| FVIIaD219A                  | 0.6 ± 0.0                   | 0.5 ± 0.0                   | ND                                 | ND         |

*Value from Ref. 20.
†ND, not determined.

It has been shown that the activating effect of TF on FVIIa is directly linked to insertion of the N terminus into the activation pocket (39). Chemical modification of the exposed α-amino group of the NH-terminal Ile153 of FVIIa prevents formation of the salt bridge with Asp143. We used carbamylation to assess the extent of burial of the N terminus in the activation pocket and found that FVIIaD212N and FVIIaDVQ were modified about 2- and 10-fold slower than wild-type FVIIa, respectively, indicating a more stably buried N terminus in both variants (Fig. 2 and Table 1). This suggests that the conformational equilibria of FVIIaD212N and FVIIaDVQ are shifted toward the catalytically active conformation compared with that of wild-type FVIIa.

We have previously shown that Ca2+ has a reduced influence on the amidolytic activity of FVIIaDVQ due to the E296V mutation (20). Removal of Ca2+ resulted in the loss of ~30% of the activity of FVIIaDVQ, whereas the amidolytic activities of all the other mutants, including FVIIaD212N, and FVIIa were reduced.

![Antithrombin inhibition assay](image)

**FIGURE 1.** Antithrombin inhibition assay. At the indicated time points, aliquots of wild-type FVIIa (△), FVIIaD212N (▲), and FVIIaDVQ (■) were withdrawn and the residual activity measured. The curves show the result of a representative experiment. Similar results were obtained in two additional experiments in which samples were withdrawn at time points different from the experiment presented (data not shown).

![Carbamylation inhibition assay using KOCN](image)

**FIGURE 2.** Carbamylation inhibition assay using KOCN. At the indicated time points, aliquots of wild-type FVIIa (△), FVIIaD212N (▲), and FVIIaDVQ (■) were withdrawn and the residual activity measured. The curves show the result of a representative experiment. Similar results were obtained in two additional experiments in which samples were withdrawn at time points different from the experiment presented (data not shown).
by more than 90%. To pinpoint the reason for the stimulatory effect of Ca2+ on FVIIa activity, we studied the importance of the interactions between Asp217 and Asp219 in the Ca2+-binding loop and Lys161 in the N-terminal tail. Replacing either Asp217 or Asp219 by Ala reduced the activity even further (about 20% residual activity). The reduced activity of the Ala mutants precluded differentiation from wild-type FVIIa in terms of AT inhibition and carbamylation, which occurs very slowly and distinctly. Non-hydrogen atoms 4456 8289

Average B-factor (all atoms, Å²) 33.1 27.1

Root mean square bond lengths (Å) 6.9 (2.1) 6.9 (2.5)

Redundancy 3.3 3.3

Completeness (%) 99.8 (97.9) 99.8 (97.9)

Space group P12_1,1 (sg 4) P12_1,1 (sg 4)

Unit cell (Å) a/a 78.36/90.00 78.41/90.00

b/b 68.56/90.22 68.79/98.28

c/c 78.89/90.22 148.58/90.00

Wavelength (Å) 1.08 1.05

Resolution range (Å) 29.19–2.20 19.90–2.70

No. of measured reflections 63,917 140,643

No. of unique reflections 34,719 42,930

Redundancy 1.8 3.3

Completeness (%) 80.3 (26.0) 98.9 (97.9)

Table 2

Crystallographic data collection and refinement statistics

|                      | sTF(I–209)-FVIIaDVQ | sTF(I–209)-FVIIaD212N |
|----------------------|----------------------|------------------------|
| Space group          | P12_1,1 (sg 4)       | P12_1,1 (sg 4)         |
| Unit cell (Å)        | a/a 78.36/90.00      | b/b 68.56/90.22        |
|                      | c/c 78.89/90.22      | wavelenght (Å) 1.08    |
| Wavelength (Å)       | 80.3 (26.0)          | 98.9 (97.9)            |
| Resolution range (Å) | 29.19–2.20           | 19.90–2.70             |
| No. of measured refl. | 63,917               | 140,643                |
| No. of unique refl.  | 34,719               | 42,930                 |
| Redundancy           | 1.8                  | 3.3                    |
| Completeness (%)     | 80.3 (26.0)          | 98.9 (97.9)            |

The structures were solved by means of the molecular replacement method using amino acid coordinates of the previously published PhePheArg-cmk inhibited FVIIa-TF structure (PDB code 1DAN) as a search model (9). One outstanding solution in the molecular replacement search was obtained for each of the scaled datasets of FVIIaDVQ and FVIIaD212N with one and two molecules, respectively, per asymmetric unit. Refinements were initially performed using rigid body minimization and followed by several cycles of restrained refinement. In the case of FVIIaD212N, non-crystallographic symmetry-restrained refinement was used with medium restraints for both main chain and side chain atoms.

The protein models were inserted into the electron densities and further model building of the covalently bound inhibitor PhePheArg-cmk was performed followed by addition of water molecules. The mutated residues were identified in the electron density. Because of poor or lacking density, a large N-terminal portion (Ala1–Gly47 in both FVIIaD212N and FVIIaDVQ) of the light chain and several loops of the second fibronectin-like domain of TF (different in the FVIIaDVQ and FVIIaDVQ-sTF structures) were included in the final structure models. Altogether, 1073 of 1230 and 539 of 615 residues in total were defined in a 2Fobs – Fc electron density map at 1σ cut-off of FVIIaDVQ/sTF(1–209) (crystallographic dimer) and FVIIaDVQ/sTF(1–209), respectively. High flexibility in these parts is assumed to be the reason for absent or poorly defined electron density. All mutations were located in the well defined protease domain, distant from the poorly defined parts, and did not appear to influence the overall fold of the protease domain as such. The protease domains of both variants displayed an excellent trace, which was also reflected in the lowest overall domain flexibility as judged from temperature factors.

The overall conformations of sTF(1–209) and the FVIIa variants and the arrangements of the light and heavy chains of the FVIIa variants were very similar to the published structure of Banner and colleagues (PDB code 1DAN) (9). However, distinct differences could be observed between the two FVIIa variants in the environment of the mutated residues in the protease domain.

In the structure of FVIIaDVQ-sTF(1–209), the three mutated residues, Asp118, Val296, and Gln298, are clearly defined in the electron density at a cutoff of 2σ (Fig. 3A). A new hydrogen bond network is established by the introduction of the side chains Asp118 and Gln298, involving the backbone carbonyls of Ile153, Glu156, Val296, and a water molecule (designated W33). This is in good agreement with a previously published model (17). This hydrogen bond network appears to exert a stabilizing effect on the N terminus in accordance with the decreased carbamylation rate of the α-amino group of Ile153 (Fig. 3, B and C). The water molecule is well defined with a very low temperature factor of 7.8 Å² compared with the average of 33.8 Å² for all water molecules in the structure. In the wild-type structure, the equivalent water molecule has a temperature factor of 21.4 Å² compared with an average for all water molecules of 39.8 Å². This indicates that the water molecule is engaged in stabilization of the activation pocket of FVIIaDVQ resulting in a more buried Ile153. Structural elements surrounding W33 in the binding pocket, including activation loop 1 (Gly285–Ala294) of the activation domain, are all stabilized in FVIIaDVQ-sTF(1–209) compared with wild-type as judged from lower temperature factors. Val296 is spatially located between mutated resi-
dues Asp^{158} and Asp^{212} positioned in the Ca^{2+}-binding loop and, interestingly, the side chain of Asp^{212} is slightly more extended toward the hydrophobic side chain of Val^{296} compared with when Glu^{296} is present (in FVIIa). Thus, a potential electrostatic repulsion between a residue in the Ca^{2+}-binding loop (Asp^{212}) and a residue immediately succeeding activation loop 1 (Glu^{296}) is eliminated by introducing valine in position 296. A hydrogen bond observed in the wild-type structure between His^{211} in the Ca^{2+}-binding loop and Glu^{296} was prevented as well by the E296V mutation, leaving the Ca^{2+}-binding loop without side chain interactions with the Gly^{283–Met^{298}} loop.

In the structure of FVIIa_{D212N-sTF-(1–209)}, residue Asn^{212} was identified in a conformation only slightly different from that of wild-type residue Asp^{212} (Fig. 4A). Altered hydrogen bond networks surrounding the mutated residue, viz. interaction with the neighboring Ser^{214}, as well as other more distant parts of the loop were apparent (Fig. 4, B and C). A well-defined network of water molecules (temperature factors: 24–29 Å²) in weak hydrogen binding distances (3.2–3.5 Å) of Glu^{296} and Asn^{212} could be observed. A hydrogen bond network between these residues might explain how the Asn mutation relieves the charge tension between side chains 212 and 296, but must be treated with caution due to the lower resolution of the x-ray data.

The changed conformation of the Ca^{2+}-binding loop appears to indirectly stabilize the activation domain and thus to mature the active site. It is important to mention that the main chain hydrogen bonds (Leu^{213}:N to Leu^{295}:CO and His^{211}:CO to Val^{297}:N) tethering the Ca^{2+} loop to the strand harboring position 296 were only slightly changed in the FVIIa_{D212N} and FVIIa_{D212N} structures compared with the FVIIa structure. The mutated residue Asn^{212} appeared to influence residues further away in the Ca^{2+}-binding loop, including residues Asp^{217}, Asp^{191}, and Glu^{220}, as well as Lys^{161} positioned in the N-terminal tail (Fig. 4, B and C, for details).

**DISCUSSION**

In this study, we have investigated the zymogenicity of FVIIa and factors that influence the insertion of the N terminus. We have identified residue Asp^{212}, located in the Ca^{2+}-binding loop of the protease domain, as yet another determinant for the zymogen-like state of FVIIa, like the Val^{158–Glu^{296–Met^{298}}} motif. Asn introduced into FVIIa_{D212N} leads to a more buried N terminus and a more mature active site as judged from faster AT inhibition and more efficient substrate cleavage. Thus, substituting these four residues shifts the conformational equilibrium toward the catalytically competent form of FVIIa.
Ca2+–induced Enhancement of the Intrinsic Factor VIIa Activity

FIGURE 4. Highlight of residues in the Ca2+-binding loop of the protease domain in the structures of FVIIaD212N (A and B; 2.7 Å) and wild-type FVIIa (C; 2.0 Å; PDB code 1DAN). The N terminus is indicated with an arrow and hydrogen bonds shown by dotted lines. 2Fo – Fo, electron density maps are shown at 1σ (blue) and 2σ (red). The mutant structure shows changes of hydrogen bond networks in the Ca2+-binding loop (Ca2+ shown as a green sphere), for example, surrounding mutated residue Asn212 and Ser214 and Glu296. A hydrogen bond is abolished between Asn212 and Ser214 because of a side chain movement of Ser214 in the mutant structure. A hydrogen bond network is introduced between Asn212, Glu296, and two strongly defined water molecules. In the wild-type structure, Asp212 along with the activation domain and an unoccupied Ca2+-binding loop.

structures of related coagulation factors, like thrombin (PDB code 1EB1), FXa (PDB code 1XKA), and FXIa (PDB code 1XX9), these four positions are occupied by amino acids that support hydrogen bond networks and we show that they can be hydrogen bond networks in the Ca2+-binding loop with improved catalytic function as the outcome. X-ray crystallography confirmed an earlier finding that the higher intrinsic activity of FVIIaDVQ correlates with increased tethering of the N-terminal tail and more stable insertion of the N terminus (17, 20), structurally explicable by a hydrogen bond network established by the mutations V158D and M298Q. Only FVIIa has an Asp residue in what corresponds to position 212, whereas FXa, Fxa, and FXIa all have Asn (Ser in thrombin). In the constitutively active enzyme FXa, Asn and Arg in positions corresponding to 212 and 296, respectively, in FVIIa, establish a hydrogen bond network similar to that observed in the FVIIaDVQ structure. Interestingly, an apparent Km effect on FX activation for FVIIaDVQ could be observed, which is in agreement with the reported proteolytic activity of FVIIaDVQ in the presence of sTF (38). This indicates that not only is Asp212 a zymogenicity-determining residue in FVIIa, but that it also is part of an exosite located in the Ca2+-binding loop.

We have previously shown that mutation E296V reduces the Ca2+ dependence of FVIIa, whereas at the same time slightly increases the burial of the N terminus, the maturation of the active site, and the amidolytic activity (20). As observed in the FVIIaDVQ structure, mutation E296V is indeed responsible for the decreased calcium dependence by abolishing side chain interactions with the Ca2+-binding loop that potentially affect activation loop 1. The functionality of Glu296 appears linked to Asp212 via charge repulsion. It has also been shown that Glu296 is linked to maturation of the catalytic cleft using an exosite-directed antibody (21, 22) whose inhibitory effect was abolished by the E296A mutation. Moreover, inhibitor binding to the active site of FVIIa appears to induce a conformational change of the Glu296 side chain.

Because we lack a zymogen-like FVIIa structure, with and without Ca2+ bound, the conformational states of Glu296 and Asp212 along with the activation domain and an unoccupied Glu210–Glu220 loop are unknown. However, the reciprocal impact of the two residues demonstrates how the interface between the Ca2+-binding loop and the tip of activation loop 1 affects N-terminal insertion. Activation loop 1 is a part of the canonical activation domain of trypsin-like proteases and it changes from a flexible to a stabilized conformation upon activation (7, 8). This loop in FVIIa has indirectly been shown to become stabilized upon TF binding as judged from decreased deuterium exchange rates of peptic fragments (40, 41). A peptide comprising residues 207–220 was shown to have a markedly reduced exchange rate upon binding to TF (corresponding to protection of two deuterons) (40). In FVIIaDVQ, the peptide-(207–220) shows an exchange rate without TF very similar to that observed for FVIIa/TF (41). This suggests that charge removal in position 296 stabilizes the hydrogen bond interactions leading to reduced Ca2+ dependence and enhanced activity.

Removal of Ca2+ reduces the activity of FVIIa to less than 10% (14), indicating the potentially essential charge-neutraliz-
Ca\textsuperscript{2+}-induced Enhancement of the Intrinsic Factor VIIa Activity

Acknowledgments—We thank Hanne B. Rasmussen for fruitful discussion of the manuscript and Anette Østergaard and Lisbet L. Hansen for excellent technical help.

REFERENCES

1. Østergaard, E. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5260–5264
2. Davie, E. W., Fujikawa, K., and Kisiel, W. (1991) Biochemistry 30, 10363–10370
3. Walsh, P. N. (2001) Thromb. Haemostasis 86, 75–82
4. Kalafatis, M., Egan, J. O., van’t Veer, C., Cawthern, K. M., and Mann, K. G. (1997) Crit. Rev. Eukaryotic Gene Expression 7, 241–280
5. Torbet, J. (1995) Thromb. Haemostasis 73, 785–792
6. Brünger, A. T., Huber, R., and Karplus, M. (1987) Biochemistry 26, 5153–5162
7. Huber, R., and Bode, W. (1978) Acc. Chem. Res. 11, 114–122
8. Bode, W., and Huber, R. (1976) FEBS Lett. 68, 231–236
9. Banner, D. W., D’Arcy, A., Chene, C., Winkler, F. K., Guha, A., Konigsberg, W. H., Nemerson, Y., and Kirchhofer, D. (1996) Nature 380, 41–46
10. Wildgoose, P., Foster, D., Schiedt, J., Wiberg, F. C., Birktoft, J. J., and Petersen, L. C. (1993) Biochemistry 32, 114–120
11. Sabharwal, A. K., Birktoft, J. J., Gorka, J., Wildgoose, P., Petersen, L. C., and Bajaj, S. P. (1995) J. Biol. Chem. 270, 15523–15530
12. Bom, V. J. J., and Bertina, R. M. (1990) Biochim. J. 265, 327–336
13. Komiyama, Y., Pedersen, A. H., and Kisiel, W. (1990) Biochemistry 29, 9418–9425
14. Persson, E., and Petersen, L. C. (1995) Eur. J. Biochem. 234, 293–300
15. Soejima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T., Higashi, S., and Iwanaga, S. (2001) J. Biol. Chem. 276, 17229–17235
16. Persson, E., Bak, H., Østergaard, A., and Olsen, O. H. (2004) Biochem. J. 379, 497–503
17. Persson, E., Kjalke, M., and Olsen, O. H. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13583–13588
18. Petrov, R. J., and Ruf, W. (2001) J. Biol. Chem. 276, 6616–6620
19. Petrov, R. J., and Ruf, W. (2002) Biochemistry 41, 9302–9309
20. Persson, E., and Olsen, O. H. (2002) Eur. J. Biochem. 269, 5950–5955
21. Dickinson, C. D., Shobe, J., and Ruf, W. (1998) J. Mol. Biol. 277, 959–971
22. Shobe, J., Dickinson, C. D., and Ruf, W. (1999) Biochemistry 38, 2745–2751
23. Persson, E., and Nielsen, L. S. (1996) FEBS Lett. 385, 241–243
24. Bolt, G., Steenstrup, T. D., and Kristensen, C. (2007) Thromb. Haemostasis 98, 988–997
25. Thim, L., Bjørn, S., Christensen, M., Nicolaisen, E., Lund-Hansen, T., Pedersen, A., and Hedner, U. (1988) Biochemistry 27, 7785–7793
26. Sorensen, B. B., Persson, E., Freskgård, P. O., Kjalke, M., Ezban, M., Williams, T., and Rao, L. V. M. (1997) J. Biol. Chem. 272, 11863–11868
27. Freskgård, P.-O., Olsen, O. H., and Persson, E. (1996) Protein Sci. 5, 1531–1540
28. Zhang, E., St. Charles, R., and Tulinsky, A. (1999) J. Mol. Biol. 285, 2089–2104
29. Cerenius, Y., Stahl, K., Svensson, L. A., Urbry, T., Oskarsson, A., Albertsson, J., and Liljas, A. (2000) J. Synchrotron Radiat. 7, 203–208
30. Kabxs, W. (1993) J. Appl. Cryst. 26, 795–800
31. Vagin, A., and Teplyakov, A. (1997) J. Appl. Crystallogr. 30, 1022–1025
32. Collaborative Computational Project (1994) Acta Crystallogr. Sect. D Biol. Crystallogr. 50, 760–763
33. Emsley, P., and Cowtan, K. (2004) Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 2126–2132
34. Patterson, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003) Acta Crystallogr. Sect. D Biol. Crystallogr. 59, 1131–1137
35. DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA
Ca\textsuperscript{2+}-induced Enhancement of the Intrinsic Factor VIIa Activity

36. Lawson, J. H., Butenas, S., Ribarik, N., and Mann, K. G. (1993) *J. Biol. Chem.* **268**, 767–770
37. Rao, L. V., Rapaport, S. I., and Hoang, A. D. (1993) *Blood* **81**, 2600–2607
38. Dickinson, C. D., Kelly, C. R., and Ruf, W. (1996) *Proc. Natl. Acad. Sci. U.S.A.* **93**, 14379–14384
39. Higashi, S., Nishimura, H., Aita, K., and Iwanaga, S. (1994) *J. Biol. Chem.* **269**, 18891–18898
40. Rand, K. D., Jørgensen, T. J., Olsen, O. H., Persson, E., Jensen, O. N., Stennicke, H. R., and Andersen, M. D. (2006) *J. Biol. Chem.* **281**, 23018–23024
41. Rand, K. D., Andersen, M. D., Olsen, O. H., Jørgensen, T. J., Østergaard, H., Jensen, O. N., Stennicke, H. R., and Persson, E. (2008) *J. Biol. Chem.* **283**, 13378–13387
42. Miyata, T., Funatsu, A., and Kato, H. (1995) *J. Biochem. (Tokyo)* **117**, 836–844
43. Sherrill, G. B., Meade, J. B., Kalayanamit, T., Monroe, D. M., and Church, F. C. (1988) *Thromb. Res.* **52**, 53–60
44. Rezaie, A. R., and Esmon, C. T. (1994) *J. Biol. Chem.* **269**, 21495–21499
45. Schmidt, A. E., Stewart, J. E., Mathur, A., Krishnaswamy, S., and Bajaj, S. P. (2005) *J. Mol. Biol.* **350**, 78–91